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Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a 
more favorable prognosis compared to other ovarian carcinomas. Nonetheless, 
current patient treatment continues to follow a “one-size-fits-all” approach. Even 
though tumor staging offers stratification, personalized treatments remain elusive. As 
ENOC shares many clinical and molecular features with its endometrial counterpart, 
we sought to investigate TCGA-inspired endometrial cancer (EC) molecular 
subtyping in a cohort of ENOC. 
Experimental Design: Immunohistochemistry and mutation biomarkers were used to 
segregate 511 ENOC tumors into four EC-inspired molecular subtypes: low-risk 
POLE mutant (POLEmut); moderate-risk mismatch repair deficient (MMRd); high-risk 
p53 abnormal (p53abn); moderate-risk with no specific molecular profile (NSMP). 
Survival analysis with established clinicopathological and subtypes specific features 
was performed. 
Results: 3.5% of cases were POLEmut, 13.7% MMRd, 9.6% p53abn and 73.2% 
NSMP, each showing distinct outcomes (p <0.001) and survival similar to 
observations in EC. Median OS was 18.1 years in NSMP, 12.3 years in MMRd; 4.7 
years in p53abn and not reached for POLEmut cases. Subtypes were independent 
of stage, grade, and residual disease in multivariable analysis. 
Conclusions: EC-inspired molecular classification provides independent prognostic 
information in ENOC. Our findings support investigating molecular-subtype specific 
management recommendations for ENOC patients; for example, subtypes may 
provide guidance when fertility-sparing treatment is desired. Similarities between 
ENOC and EC suggest that ENOC patients may benefit from management 
strategies applied to EC and the opportunity to study those in umbrella trials. 
Statement of translational relevance: 
The translation and implementation of molecular research findings in cancer 
management remains a challenge. This is especially ambitious in uncommon 
cancers, such as endometrioid ovarian carcinoma (ENOC). Compounded by 
historical inaccuracies in diagnosis, ENOC is one of the least well studied histotypes 
of ovarian carcinoma, with little evidence available to guide treatments or identify 
patients likely to experience excellent outcomes versus those with aggressive 
disease. ENOC shares considerable molecular and histological similarity with 
endometrial carcinomas (EC), in particular endometrioid EC (EEC), with endometrial 
tissue well accepted to be the origin of both diseases. The similarity between ENOC 
and EC suggests that clinical developments from the much larger EC patient cohort 
could be rapidly translated to the less common ENOC population. In this context, we 
provide direct evidence that molecular subtypes defined in EC also exist in ENOC 
with equivalent features and clinicopathological behavior. Our data provide a basis to 
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investigate molecularly stratified management strategies in ENOC and suggest 
collective research and subtype-specific trials across EC and ENOC may provide 
advantages to both cancers. 
Introduction 
Today, the scientific community widely agrees that ovarian carcinoma is a 
heterogeneous disease and that different histological types are best considered as 
different disease entities [1]. The next step towards type-specific treatment 
approaches is to further stratify each ovarian carcinoma histotype. The Cancer 
Genome Atlas research network (TCGA) study on ovarian carcinomas in 2011 
brought considerable insights into the most common tubo-ovarian high-grade serous 
carcinoma (HGSOC) histotype [2]. In-depth genomic studies of the other histotypes 
are few and far between. 
Endometriosis-associated ovarian carcinomas, specifically endometrioid and clear 
cell histotypes, are collectively the second most common forms of ovarian carcinoma 
and account for a combined ~20% of ovarian carcinomas [3, 4]. Both are believed to 
originate from endometrial cells and most frequently thought to develop via an 
endometriosis intermediate [5, 6]. Endometrioid ovarian carcinoma (ENOC), is near 
identical to its endometrial endometrioid carcinoma (EEC) counterpart with respect to 
theory on origin, common synchronous occurrence, similar genotype, phenotype, 
risk factors, and near-indistinguishable histopathological presentation [7-12]. 
Compared to HGSOC, women with ENOC are on average 6 years younger (more 
often premenopausal), diagnosed at earlier stage (stage I/II in 80% of cases) and 
show higher overall survival rates (~ 80% 5-year survival) compared to most other 
histotypes of ovarian carcinomas [13-15]. 
Despite these differences between dominantly poor outcome and dominantly 
favorable outcome entities, consensus guidelines for patient management and 
chemotherapy still parallel those of the more aggressive HGSOC [16, 17]. The 
similarities between endometrial carcinoma (EC), specifically EEC, and ENOC 
suggest EC/EEC may provide more reliable benchmarks for the management of 
ENOC. TCGA study on EC recently proposed a prognostic molecular stratification 
scheme for EC based on unique genomic phenotypes. One group is defined by 
pathogenic mutations in the exonuclease domain of DNA polymerase epsilon 
(POLE) and an ultramutated genome, another by deficiency in the DNA mismatch 
repair pathway and a microsatellite unstable/hypermutated genome, the final two 
groups are split by fraction of their genomes involved in copy number alterations: 
copy-number low and copy-number high [18]. Following the TCGA study, two groups 
simultaneously derived near-identical minimal-biomarker based surrogates for the 
TCGA EC molecular subtypes [19-21]. The end result, an algorithm referred to as 
the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), uses 
immunohistochemistry markers and targeted sequencing of POLE to identify three 
molecular subtypes: (1) POLE mutant “POLEmut”: defined by pathogenic POLE 
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exonuclease domain mutations that identify a group with favorable outcome and an 
ultramutation phenotype; (2) mismatch repair deficient “MMRd”: defined by IHC 
markers for DNA mismatch repair complex (MSH1, PMS2, MSH2, and MSH6) and 
identifies cases with microsatellite instability and a corresponding hypermutation 
phenotype; and (3) p53 abnormal subtype “p53abn” (also referred to as p53-aberrant 
or p53-mutant): defined by abnormal p53 IHC staining pattern and correlating with 
copy-number high genomic phenotype. A fourth group without any of these three 
characteristics is correlated with the copy-number low class from the TCGA EC 
classification, also known as no specific molecular profile class (NSMP). In EC, 
ProMisE classification is proven to be not only prognostic but also predictive and is 
expected to bring advantageous changes into clinical practice of EC patients [21]. 
Similarities between EC and ENOC have led several groups to hypothesize that 
ENOC could be stratified into the same four molecular subtypes seen in EC. Parra-
Herran et al. showed the general feasibility of this approach, with their conclusions 
hindered by a small cohort [22]. Cybulska et al. demonstrated that the genomic 
phenotypes of EC subtypes could be captured in a small cohort of ENOC [23]. 
Together these observations strongly support a need for validating a molecular 
stratification scheme in ENOC. Opportunities may exist both to reduce overtreatment 
(unnecessary chemotherapy), in patients with expected excellent outcomes, while 
still identifying patients in need of more aggressive treatment (avoid undertreatment). 
The aim of the current study was to validate the frequency of biomarker-defined EC 
molecular subtypes, and their prognostic patterns, to the current set of ENOC clinical 
risk factors such as stage, grade and residual tumor burden. 
Methods 
Study cohorts 
Available cases with clinically identified primary ovarian carcinoma and a diagnosis 
of endometrioid histotype were identified from clinical and/or research databases 
from 9 centers across 4 countries (n=604). Tissue samples were provided from 
Canadian and European centers: Department of Women’s Health, Tuebingen 
University Hospital, Germany (GER); Department of Gynecology and Gynecologic 
Oncology, Kliniken Essen Mitte, GER; Department of Obstetrics and Gynecology, 
Heidelberg University Hospital, GER; Department of Gynecology and Obstetrics, 
Medizin Campus Bodensee, Friedrichshafen, GER; Department of Gynecological 
Oncology, Barts Health National Health Service Trust, London, United Kingdom 
(UK); Department of Gynecology University Medical Centre, Leiden, the Netherlands 
(NL); Department of Obstetrics and Gynecology, University Medical Center 
Groningen, NL; the OVCARE gynaecological tissue bank, Vancouver, CA; and the 
Canadian Ovarian Experimental Unified Resource (COEUR)[15]. All contributing 
institutions approved collection and use of materials and associated clinical data 
through local research ethics boards. The project was conducted in compliance with 
the Canadian Tri-Council Policy Statement on Ethical Conduct for Research 
 
6 
Involving Humans (TCPS2, 2018) and Declaration of Helsinki. Study samples from 
Canada, the United Kingdom, and Germany were obtained with written informed 
consent. A subset of German study samples, where consent was not reasonably 
achievable (e.g. deceased), and specimens from The Netherlands were obtained 
with institutional ethics board approved waiver of consent. Studies except for those 
from NL and UK used tissue microarrays (TMAs) for immunohistochemical (IHC) 
markers. UK and NL studies used full section IHC (Figure S1A).  
All samples were subjected to WT1 and p53 immunohistochemistry. Cases showing 
both WT1 expression and p53 abnormal/mutant staining pattern (n=36) or 
uninterpretable/missing (n=35) results were considered likely HGSOC [24, 25] and 
excluded. Finally, after accounting for any biomarker assessment failures, complete 
subtyping was available on 511 cases and all results are restricted to this series 
(Figure S1B). 
We analyzed the cohort as a whole as well as considering a subset of low-stage 
(FIGO I-IIA [17]) cases. In the latter group we assumed no residual disease if 
debulking status was not reported (n=73), whereas if residual disease was reported 
after primary debulking surgery, we assumed cases were under-staged (n=9) and 
reclassified these as advanced-stage, not otherwise specified (NOS). 
Reclassification was done as the presence of residual tumor is generally 
incompatible with low-stage. We were unable to resolve discrepancies in stage IIC 
(FIGO 2009; n=51) which may have resulted in a subset of these cases restaged to 
stage IIA (FIGO 2014; low-stage for our analysis); these were retained as advanced-
stage as were stage II not otherwise specified (NOS; n=17). A single case was also 
reported to have dedifferentiated features, this case was omitted from grade-specific 
analyses. 
Molecular subtype assignment 
Immunohistochemistry 
Due to contributions from various centres there are slight differences in assays 
performed on different cohort as outlined below (see also Figure S1 and Table S1). 
MMRd was assigned by IHC using 4 mismatch repair pathway markers. Staining 
was performed on a Dako Omni platform with 30 min heat-induced pre-treatment 
using high retrieval buffer pH using the Omnis protocol H30-10M-30 with the ready-
to-use clone ES05 (DAKO) for MLH1; H20-10R-20 with the ready-to-use clone EP51 
(DAKO) for PMS2; H30-10M-30 with the ready-to-use clone FE11 (DAKO) for MSH2; 
and H30-10R-30 with the ready-to-use clone EP49 (or EPR3945) (DAKO) for MSH6. 
Interpretation of mismatch repair staining was dependent on retained nuclear 
staining in non-tumor cells on each evaluated core (internal positive control). Cases 
were considered mismatch repair deficient (MMRd) if absence of nuclear staining in 
tumor cells with retained internal control was observed for any individual core on any 
of the following markers: MLH1, PMS2, MSH2, or MSH6. [26, 27] 
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p53abn was assigned by surrogate p53 IHC, which has been established as an 
accurate predictor of the TP53 mutation status [28]. IHC for p53 was performed on a 
Dako Omni platform with 30 min heat-induced pre-treatment using high pH retrieval 
buffer and Omnis protocol H30-10M-30 with the ready-to-use clone DO-7 (GA61661-
2; DAKO). Results were interpreted according to guidelines of the International 
Society of Gynecological Pathologists, with three abnormal patterns (overexpression, 
complete absence in tumor cells but retaining internal control, and cytoplasmic with 
unequivocal cytoplasmic and variable nuclear staining) and wild type p53 
represented by variable intensity and distribution of staining in tumor cell nuclei [29]. 
POLE sequencing 
DNA was extracted from FFPE tumor tissue sections using a modified procedure 
with the Qiagen QIAamp FFPE DNA extraction kit as described previously [11, 30]. 
Primer sets for Sanger sequencing and next-generation sequencing (NGS) 
strategies can be found in Table S2. 
For all studies except UK, NL, and Heidelberg: three redundant sets of primers were 
designed to cover common POLE exonuclease domain hotspots in exons 9, 13 and 
14 (p.P286R, p.M295R, p.S297F, p.V411L, p.L424I, p.A456P, and p.S459F) 
described to be pathogenic [31] in a tailed-amplicon sequencing strategy [32]. 
Sequencing of overlapping redundant amplicons was used to mitigate fixation errors 
common to FFPE-derived tissues [33]. PCR products were amplified using 
QuantStudio 6 Flex Real-Time PCR System with 2.5 ng of DNA. Amplicons were 
pooled on a per-sample basis and each sample pool was barcoded with unique 
indexes. Following indexing, all samples were pooled equimolar for sequencing on a 
MiSeq instrument (Illumina) using a 300 cycle v2 sequencing kit. Median coverage 
was >1,700X (per amplicon) (Table S3) over hotspots of interest. Mutations were 
called across primer sets and manually verified in bam files to ensure at least two (of 
three) amplicons contained the variant of interest. 
For studies from UK, NL, and Heidelberg Sanger sequencing was performed over 
POLE hotspots noted above and additionally p.P436R and p.M444K. Technical 
repeat was performed for any observed variants (see also Figure S1A). Note that 
neither NGS, nor Sanger, strategies provided coverage for rare pathogenic variants 
in Exon 11 (p.F367S, p.D368Y) [31]. 
POLE variants were classified as (1) germline based on reference to dbSNP and 
consistent allele frequency; (2) pathogenic somatic variants based on presence in 
COSMIC and corroborating data from genomic studies with evidence of an 
ultramutated phenotype [18, 23]; (3) non-pathogenic somatic variants that are 
observed in other genomic studies but without an ultramutated phenotype; and (4) 
somatic variants of unknown significance (VUS) for other somatic variants that have 
not previously been reported with corroborating genomic data. Only pathogenic 




We followed a classification schema proposed for EC in TCGA EC study, 
considering POLEmut first followed by MMRd, p53abn and finally NSMP. In rare 
cases with multiple possible classes we prioritized features in the order presented by 
TCGA EC study [18] and recommended for ProMisE using surrogate biomarkers [21, 
34]. 
Statistical Analysis 
Chi-squared test was used to evaluate univariable associations for categorical 
variables and Welch’s one-way test for continuous variables. Differences in 
univariable survival outcomes were analyzed using the log-rank test. To evaluate the 
independent prognostic significance of molecular classification, the Cox proportional 
hazards model is used, adjusting for known clinicopathological risk variables. A Firth 
bias reducing correction is applied in the calculation of hazard ratio estimates, when 
more than 80% censoring is present in any one category of the variable of interest. 
The profile likelihood is used to calculate confidence intervals. Statistical significance 
was evaluated by the omnibus likelihood ratio test in the Cox models. Only 
observations with complete cases (by list-wise deletion) were used in modeling. 
Statistical significance level is set to 0.05. P-values are two-sided, not corrected for 
multiple comparisons, and truncated to an inequality if less than 0.001. All statistical 
analyses were performed using the statistical software R (R Core Team, 2019), R 
version 3.5.3 (2019-03-11), and relevant R Packages [35]. 
All analyses were done only on ENOC patients with full subtype information available 
(n=511). The cohort was first examined in the context of clinicopathological features: 
age, stage (FIGO), grade (1/2 vs 3), residual disease (no visible macroscopic vs any) 
and adjuvant chemotherapy (none vs any). Outcome data included overall survival 
(OS), disease-specific survival (DSS) and progression free survival (PFS), where 
progression was determined by the treating physician. In all cases, the variable was 
calculated as time from diagnosis to time of event (death/progression) or censoring. 
Follow up that exceeded 10 years (or 5 years as noted below) was right censored as 
at December 31st of the 10th year post-diagnosis to minimize ascertainment bias 
and ensure non-informative censoring. Molecular subtyping was then analyzed alone 
and in context with noted features. Finally, ENOC data was compared to data from 
EC studies [19, 30, 36]. 
Results 
Cohort Description 
Patients were diagnosed between 1985 and 2018 (Table S3) Median follow-up time 
(OS) was 5.34 years (reverse Kaplan-Meier). Median age was 55 years, 57% of 
patients presented at low-stage (FIGO I-IIA), 47% were G1, 34% G2 and 20% G3. 
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Clinicopathological variables were not significantly different between European and 
Canadian cohorts (Table S4). 
Survival analysis using established risk factors 
OS, DSS, and PFS were all significantly different between FIGO stages and patients 
with or without residual disease. Outcomes (OS, DSS, PFS) were all more favorable 
in patients with low-stage disease and no residual tumor respectively (p<0.001 for 
all; Figure 1A, B; Figure S2). Prognostic value of grade was significant in OS, DSS 
and PFS analyses for the full cohort (p<0.001 for all; Figure 1C, Figure S2), with 
grade 3 cases performing worse. However, when restricted to low-stage, grade was 
no longer prognostically significant (p=0.538) (Figure 1D, Figure S2). 
Multivariable Analysis of established risk factors is shown in Table S5. With a DSS 
hazard ratio (HR) of 3.5, stage was the strongest prognosticator across ENOC 
patients in this cohort (p=0.001) while residual disease (HR=3.1, p<0.001) and grade 
(HR=2.17, p=0.006) were also significant. Similarly, stage, grade and residual 
disease retained significance for OS and PFS. Age at diagnosis was of borderline 
significance for OS (HR=1.02, p=0.042), but was not significant for DSS or PFS 
(Table S5). 
Molecular Subtype Assignment 
Of 533 cases with sufficient tissue for molecular assignment, POLE sequencing 
failed or was uninterpretable in 13 cases, MMR IHC was uninterpretable due to lack 
of internal control in 8 cases, and a single case was disqualified from classification 
due to uninterpretable p53 staining. 511 cases were fully subtyped and all results are 
restricted to this set (Figure 2A, Figure S1B). 18 cases (3.5%) harbored pathogenic 
POLE mutations (POLEmut; Figure 2A-B; Figure S3; Table S3). All 18 POLEmut 
cases were p53 wild type and MMR proficient by IHC surrogates. A total of 70 cases 
(13.7%) were assigned to MMRd, including 8 cases that were also p53 abnormal by 
IHC and 6 cases with heterogeneity in MMR marker scores across multiple replicate 
TMA cores.  49 cases were assigned to p53abn (9.6%; not including 8 assigned to 
MMRd), two of which showed heterogeneity in p53 IHC between TMA cores 
suggesting potential subclonality of p53 mutation. The remaining 374 cases (73.2%) 
were NSMP (Figure 2A-B; Figure S3).  
In a subset of 15 cases, whole genome sequencing data was available from a 
previously published study [37]. This enabled us to verify the expected genomic 
profiles (Figure S4). 
Clinicopathological associations of molecular subtypes 
Significant univariable association is observed between age, stage, grade, residual 
disease and post-surgical chemotherapy and molecular subtype (Table 1; see also 
Figure 2B and S3). Patients with POLEmut ENOC were generally younger (median: 
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45 years), diagnosed at lower stage and grade. The oldest subset of patients fell into 
the p53abn class (median: 57 years) and was typically diagnosed at higher stage 
and grade. Accordingly, 33% of patients with POLEmut ENOC received no post-
surgical treatment compared to 17% with p53abn ENOC.  
Survival Associations of Molecular subtypes 
OS and PFS data were available for 505 cases, DSS data for 497 cases. Kaplan-
Meier curves show distinct survival outcomes in all three endpoints (Figure 2C-D-E, 
p<0.001 for all). No disease-specific deaths were observed in POLEmut patients, 
one POLEmut patient died of a non-disease related cause. p53abn patients had a 
disease-specific 10-year-survival-rate of only 39% (Table 2). For POLEmut, median 
overall survival time is not reached, in NSMP group it is 18.1 years, in MMRd group 
12.3, in p53abn group 4.7 years. 
After adjusting for currently used clinical risk factors (stage, grade, age, residual 
disease) and post-surgical chemotherapy in multivariable analysis, molecular 
subtypes were still statistically significant for OS, DSS and PFS (p<0.001) (Table 2). 
Amongst clinicopathological features, multivariable analysis showed age to be 
significant only for OS, while post-surgical chemotherapy retained significance only 
for OS and PFS (Table 2). 
Stratified analysis of low-stage ENOC 
In univariable analysis of low-stage ENOC, molecular subtypes were associated with 
substages (p=0.032) but not with age, grade, or post-surgical chemotherapy (Table 
S7). Outcomes of molecular subtypes (OS, DSS and PFS) were still statistically 
different (Figure 2F,G,H). In multivariable analysis, correcting for age, stage, grade, 
and post-surgical chemotherapy, subtypes retained significance for OS (p=0.004), 
DSS (p=0.034) and PFS (p=0.048). However, amongst other variables only grade 
was significant in OS (Table S8). 
We further stratified outcomes of low-stage ENOC patients (FIGO IIA or less) across 
molecular subtypes in two subsets: one less likely to be recommended for adjuvant 
chemotherapy (stage IA/B G1/2) and the other more likely to be so (FIGO IA/B G3, 
IC/IIA) according to current international guidelines [16, 17] (Table 3). POLEmut 
ENOC patients had neither disease specific deaths nor progression. In the subset 
more likely to be recommended for adjuvant chemotherapy, p53abn and MMRd 
ENOC patients had proportionally more disease specific deaths, if they did not 
receive adjuvant treatment. Amongst low-stage NSMP there were 3 (4.7%) DSS 
events (vs. 0%) in the group that did not receive chemotherapy, and would generally 
not have been referred (Table 3). 
Comparison of molecular subtyping in ENOC and EC 
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We pooled EC data from previous studies [19, 30, 36] and further separated EEC 
because of similarities to ENOC. Subtype distribution differed between ENOC and 
both EC and EEC (chi-square, both p<0.001). Compared to all EC, POLEmut, 
MMRd, and p53abn cases were all less frequent in ENOC, while the NSMP group 
was substantially larger (Figure 3A). However, when we restricted to EEC, the 
number of p53abn cases (5.6%) dropped in comparison to ENOCs (9.6%), trends in 
the other subtypes remained unchanged (Figure 3A). 
Patients with EC, or EEC, were consistently older than those with ENOC across all 
molecular subtypes (Table S9, S10). ENOC POLEmut, MMRd and NSMP patients 
presented at a higher stage compared to EC or EEC. Stage was not significantly 
different in p53abn cases when comparing ENOC to all EC but was higher in ENOC 
compared to EEC (Table S9, S10). Both p53abn and MMRd EC were of higher 
grade than the corresponding subtypes of ENOC. Grade was not significantly 
different in NSMP and of borderline significance in POLEmut subtype (Table S9, 
S10). 
We further compared 5-year-censored outcomes between ENOC (Table S11) and 
EC/EEC (Figure 3B). The proportion of surviving patients across all molecular 
subtypes was generally similar in ENOC compared to EC/EEC, with the exception of 
p53abn ENOC performing worse than p53abn EEC (5-year-DSS: 51% vs 70%; 
Figure 3B). 
Discussion 
This is the largest study to report molecular stratification of ENOC by translating a 
classification tool previously validated in EC [19-21, 30, 36]. We show that analogous 
molecular subtypes are prognostic in ENOC in all 3 critical endpoints (OS, DSS, and 
PFS). These findings validate and improve upon previous smaller studies [22, 23], 
specifically: we show that subtype to outcome associations remain significant in 
multivariable analysis independent of age, stage, grade, residual disease and post-
surgical treatment. Furthermore, our stratified analysis suggests molecular subtype 
may provide particularly valuable information for low-stage patients where we were 
unable to show a significant impact for grade. Thus, molecular subtypes have the 
potential for immediate clinical translation, informing clinical trials that seek to test 
de-escalation or escalation of adjuvant therapy in specific low-stage patients. 
Within molecular subtypes POLEmut cases showed an excellent outcome while 
patients with p53abn ENOC had the lowest survival rates even at low stage. NSMP 
and MMRd patients had largely equivalent, intermediate outcomes when the entire 
cohort was considered. However, in low-stage cases the outcome of NSMP patients 
tends to be more favorable compared to MMRd cases with noticeable differences in 
OS vs DSS/PFS. The generally more favorable outcomes in ENOC, in contrast with 
the more common HGSOC, require monitoring of both DSS and OS.  
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In comparison to EC, the Kaplan-Meier curves and 5-year-DSS-rates of molecular 
subtypes in ENOC were similar to those in EC [18-21, 30, 36]. ENOC were generally 
diagnosed at higher stage. Possible explanations include a less restricted access to 
the peritoneal cavity and obscured symptoms (e.g. lack of abnormal uterine 
bleeding). An exception is p53abn (non-endometrioid) EC, which appears to have 
aggressive spread regardless of anatomical borders. ENOC also tended to be 
younger than EC regardless of molecular subtype. While non-endometrioid EC are 
known to be older at diagnosis than EEC [38], the age difference was still substantial 
when comparing ENOC with EEC. Major epidemiological risk factors such as obesity 
and hormonal exposures are common to both EEC and ENOC [39, 40]. A plausible 
explanation may be the opportunity of occult/non-invasive EC (and hyperplastic) 
lesions to be shed during menstruation along with the functionalis of the 
endometrium in premenopausal women, thus contributing in part to the delayed 
onset of EC. In contrast, ovarian ENOC precursor lesions, such as endometriosis, 
would not be shed and may allow persistence of (pre)neoplastic cells. Such events 
are similar to the paradigm described as precursor escape in HGSOC [41]. 
Alternatively, as-yet undefined characteristics of a distinct, younger, population may 
also contribute to greater risk of ovarian disease. 
POLEmut patients had excellent outcomes even at advanced-stage, and were less 
frequently observed than in EC/EEC but consistent with a previous study in ENOC 
[12]. Some early reports in EC may have overestimated the frequency of the 
POLEmut subtype by reporting non-pathogenic POLE mutations without evidence of 
ultramutator genotype, but regardless our ENOC POLEmut frequency is still lower 
(3.5% vs. range 6-9.4%). In EC it has also been suggested that pathogenic POLE 
mutations are quite early events [42]. While our design precludes a conclusive 
statement on whether POLE mutations are truncal in the context of ENOC, the 
variant frequency from informative cases would generally not favor emergence of 
POLE mutations in rare subclonal populations (Table S3). It should also be noted 
that our sequencing strategy may have missed a subset of less common pathogenic 
POLE mutations (see methods). In EC, retrospective data suggest no additional 
value of adjuvant chemotherapy in POLEmut EC cases [43]. A prospective clinical 
trial PORTEC4a (NCT03469674) is currently underway to investigate treatment de-
escalation in EC. Results are equally relevant for ENOC. Subtype may be useful if 
fertility-preserving procedures are considered, POLEmut and p53abn currently stand 
at extremes, whereas additional data is still needed for NSMP. 
MMRd ENOC were also less common than observed in EC, and in particular in EEC. 
The difference appears in part due to reduced proportion of MLH1/PMS2 deficient 
cases in ENOC suggesting somatic hypermethylation of the MLH1 promoter may be 
more prevalent in EEC compared to ENOC. Nonetheless, our results corroborate 
universal MMR biomarker testing in ENOC to screen for Lynch syndrome [44, 45]. 
MMRd ENOC patients may be eligible for immune checkpoint inhibitor therapy, 
either on trial or as part standard of care (FDA, HC) [46, 47]. In following the EC 
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subtyping guidelines we also chose to retain 8 so-called “multiple classifier” 
specimens with abnormal p53 IHC and MMRd in the MMRd subtype [34]. Within EC 
such dual-class cases have outcomes similar to MMRd. Unfortunately, our small 
cohort of 8 cases (7 with follow up, 2 of which were censored prior to 2 years) is 
insufficient to address this rare but curious group. 
p53abn ENOC were substantially less common than p53abn EC, which appears to 
be entirely due to non-endometrioid p53abn EC, as the frequency of p53abn EEC 
was much lower than p53abn ENOC. We also observed subclonality in p53 mutation 
(2/49 ENOC) which may indicate this alteration is not an obligate truncal/tumor 
initiating event. Because of our use of IHC (combination of WT1/p53 to identify 
HGSOC) we can exclude that misclassification of HGSOC as ENOC caused the 
higher frequency in ENOC than EEC. However, we cannot exclude that 
misclassification of p53abn EEC as non-endometrioid EC may have contributed to 
the low p53abn EEC frequency. Objective, biomarker-integrated histotype diagnosis 
across EC may be needed prior to further validation.  
Finally, the substantially higher frequency of tumors with NSMP may also suggest 
additional, yet to be identified, features within this subtype provide a particular 
advantage in colonizing the ovarian microenvironment. While NSMP ENOC have 
generally a favorable prognosis, some cases in the low-stage/low-risk setting which 
did not receive adjuvant therapy did succumb to the disease suggesting there is in 
fact a broad spectrum of outcomes within this subtype. As the NSMP is considerable 
(73.2% of cases), with many having no progression or disease-specific death events, 
additional biomarkers are needed to identify specific patients within this group that 
may have no additional benefit from chemotherapy (potential overtreatment) versus 
those in need of more aggressive management [14, 48-50]. 
Our larger cohort also allowed us a unique opportunity to evaluate the current 
standard of ovarian carcinoma clinical/prognostic risk factors within the ENOC 
histotype. As expected, patients were generally younger (mean: 57 years) than 
expected for HGSOC patients (mean: 60-62 years[2, 14, 15] or older [51]). Similarly, 
our cohort of ENOC were 81% stage I/II, in contrast to HGSOC where stage I/II 
cases are relatively rare (mean:18-19.5%) [14, 15]. We confirmed the prognostic 
relevance of clinically established factors (stage, residual disease and grade) in 
ENOC patients. This provides validation to the WHO’s endorsement of FIGO grading 
for ENOC based on extrapolation of the same schema used for EEC, without 
previous studies showing independent prognostic significance [52]. Despite being 
the first to show significance of grade in multivariable analysis, it is important to note 
that we were unable to replicate this association within the important low-stage 
subset. However, molecular subtype is prognostic at low-stage and may have the 
potential to better inform treatment guidelines in this group by supplementing or 
replacing grade. For example, 15% of p53abn ENOC were assigned to grade 1 and 
some of these cases did not receive adjuvant therapy. Molecular subtype may have 
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stronger prognostic association by virtue of identifying key drivers of oncogenic 
pathways in ENOC. Objective precision and reproducibility has been demonstrated 
for the key subtype biomarker used in our study, something that has been lacking for 
grade [53-56].  
Particular strengths of our study are its size, totality in clinicopathological annotation, 
relatively long follow up time, biomarker-integrated review for inclusion of ENOC 
histotype, and use of validated biomarkers for molecular subtype classification. 
However, even with a long window for clinical follow-up data (almost 35 years for 
one cohort) a large fraction of our series was eventually lost to follow up. We also 
lacked substantial overlapping whole genome data to support genomic phenotypes; 
in particular, we lacked functional data on two observed POLE VUS (p.S421N and 
p.D462E) leading to them being omitted from POLEmut. Still, all cases with 
overlapping genomic data were concordant with predicted phenotypes. Despite a 
large cohort we did not have sufficient number or heterogeneity in management to 
properly address concerns around under- vs over-treatment. 
Finally, the conclusions above generally follow the assumption that both EEC and 
ENOC are etiologically the same disease - presenting at different anatomical sites - 
a theory supported by substantial, albeit circumstantial, evidence [7-12]. While 
molecular classification clearly brings valuable prognostic data, further investigation 
of the broad range of ENOC covered by the NSMP class is still needed, as is a 
validation of our classification results with particular emphasis on low-stage disease 
and potential to modify treatment guidelines. Such studies stand to bring 
considerable precision to cancer management decisions by both healthcare 





Figure 1: Kaplan-Meier survival curves for disease-specific survival (DSS) in 
endometrioid ovarian carcinoma (ENOC) showing log-rank p-values and numbers 
and numbers at risk. Cross hatches represent censoring and shaded areas 
represent the 95% confidence bands. (A) DSS for the entire cohort by FIGO Stage I, 
II, III, IV. (B) DSS for entire cohort by presence of residual disease, where “none” is 
defined as no visible macroscopic disease after primary debulking surgery. (C) DSS 
for the entire cohort by Grade 1, 2, 3 (D) DSS in low-stage (IIA or less) ENOC with 
categories split by Grade 1, 2, 3. Similar results, including detail on overall and 
progression-free survival can be found in supplemental Figure S2. 
Figure 2: Results from molecular classification of ENOC, note that all included 
samples had interpretable IHC data for MMR markers and p53, as well as POLE 
sequencing. (A) Molecular subtype assignment using surrogate biomarkers 
described for endometrial carcinoma and classification scheme following the current 
recommendations for endometrial carcinoma (McAlpine et al., 2018) prioritizing 
POLEmut, then MMRd, then p53abn and finally NSMP molecular subtypes. (B) 
Oncoplot outlining our full cohort of cases (in columns) along with molecular class, 
individual biomarkers that define each class, as well as clinicopathological features. 
A full-size version of the oncoplot can be found in Figure S3. For MMR data, a 
subset of cohorts used a two-marker IHC strategy on full section slides, whereas the 
majority of specimens were subject to four-markers IHC in TMA format. See also 
supplemental Figure S1. (C-D-E) Illustrate OS and PFS (POLEmut (n=18), NSMP 
(n=370), MMRd (n=69), p53abn (n=48)), and DSS (POLEmut (n=17), NSMP 
(n=365), MMRd (n=69), p53abn (n=46)) Kaplan-Meier survival curves, respectively, 
by molecular subtype for the entire cohort. (F-G-H) similarly illustrate OS and PFS  
(POLEmut (n=11), NSMP (n=216), MMRd (n=28), p53abn (n=19)), and DSS  
(POLEmut (n=11), NSMP (n=215), MMRd (n=28), p53abn (n=19)) Kaplan-Meier 
survival curves, respectively, restricted to low-stage (FIGO I – IIA) ENOC cases. 
Numbers at risk for C to H can be found in Table S6. 
Figure 3: Comparison of ENOC and EC/EEC molecular subtypes, EC/EEC data are 
combined from Talhouk et al., 2015, Talhouk et al., 2017, and Kommoss et al., 2018. 
(A) Proportions of surrogate-biomarker defined molecular subtypes in ENOC, EC 
and EEC. (B) 5-year survival rates for ENOC, EC and EEC. 
Table 1: Univariable associations between molecular subtypes and 
clinicopathological variables in ENOC. 
Table 2: 10-year-survival-rates, Hazard Ratios and multivariable survival of 
molecular subtypes in ENOC. 
Table 3: Number (and percent) of disease-specific events in low-stage (FIGO I – IIA) 
ENOC patients compared to their respective actual treatment profile, whether or not 
 
16 
they received adjuvant chemotherapy. For each of the four molecular subtypes we 
further display rows defined by current guidelines (Colombo et al., 2019, Armstrong 
et al., 2019) for treatment with adjuvant chemotherapy, i.e. group less likely to be 
referred for adjuvant chemotherapy (FIGO IA/B and Grade 1 or 2) versus group 
more likely to be referred for adjuvant chemotherapy (FIGO IA/B and G3, FIGO 
IC/IIA any grade). 
Supplemental Figure Legends 
Figure S1: Workflow of (A) biomarker analyses and (B) case numbers for each 
contributing center. *London performed whole section IHC for PMS2, MSH6, WT1, 
p53; Groningen and Leiden performed whole section IHC for MLH1, PMS2, MSH6, 
WT1, p53. 
Figure S2: (A) OS and (E) PFS of ENOC patients by FIGO Stage I, II, III, IV. (B) OS 
and (F) PFS of ENOC patients by any or no residual disease after surgery. (C) OS 
and (G) PFS of ENOC patients by grade in cases of all stages and (D, H) in low-
stage (FIGO IIA and less) cases. 
Figure S3: Enlarged version of the oncoplot from Figure 2B outlining our full cohort 
of cases (in columns) along with molecular class, individual biomarkers that define 
each class, as well as clinicopathological features. Note that for MMR IHC markers, 
a subset of cohorts used a two-marker IHC strategy on full section slides, whereas 
the majority of specimens were subject to four-markers IHC in TMA format. See also 
supplemental Figure S1. 
Figure S4: Comparison of whole genome sequencing (WGS) data and molecular 
subtype derived from surrogate IHC and POLE sequencing biomarkers. Overlap of 
surrogate biomarker and WGS was available for 1 POLEmut, 1 p53abn, 5 MMRd 
(including 3 that also had abnormal p53 staining), and 8 NSMP. WGS data, COSMIC 
signature probabilities, and copy number data as reported in supplemental materials 
in Wang, Bashashati, et al. Nat Genet. 2017 Jun;49(6):856-865. While our data are 
anecdotal due to small numbers they are consistent with reports from endometrial 
cancer. (A) Shows the contribution of a dysfunctional POLE DNA damage profile 
(S.POLE) COSMIC signature #10 across samples with surrogate biomarker based 
molecular subtypes. (B) Shows the contribution of a mismatch repair deficient DNA 
damage profile (S.MMR) COSMIC signature #6 across samples with surrogate 
biomarker based molecular subtypes. (C) Shows the fraction of the genome involved 
in copy number changes as a sum of amplifications (AMP; with copy number ≥ 4), 
deletions (Del), and Loss of heterozygosity events (LOH; including copy-neutral and 
allelic imbalance). 
Table S1: Number of cases, study design, year of diagnosis, month/year of last 
follow-up, constitutional reviewer (Initials), IHC based review (Initials) and TMA 
format per center. *9 cases from 2014-2016 were diagnosed only by the local gyn-
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path specialist). **Some cases were represented on more than one TMA. All scores 
from all available TMA cores of a case where considered for IHC results. 
Table S2: Primer sequences for Sanger sequencing (NL/UK and Heidelberg cohort) 
and NGS strategy (CS1 and CS2 tailed). 
Table S3: List of all observed POLE variants. 
Table S4: Univariable associations between Cohort and clinicopathological features 
comparing Canadian and European cohorts. 
Table S5: Multivariate analysis of established risk factors (age, FIGO stage, grade, 
residual disease) in endometrioid ovarian carcinoma. 
Table S6: Numbers at risk of OS, PFS and DSS KM plots of the molecular subtypes 
in the cohort of all stages as well as low-stage cases (FIGO Stage I-IIA) in Figure 2 
C to H. 
Table S7: Univariable survival of endometrioid ovarian carcinoma molecular 
subtypes and clinicopathological variables in low-stage (FIGO I-IIA). 
Table S8: Multivariable survival of endometrioid ovarian carcinoma molecular 
subtypes and clinicopathological variables in low-stage (FIGO I-IIA). 
Table S9: Univariable Associations between Molecular subtypes in EC and ENOC. 
Table S10: Univariable Associations between Molecular subtypes in EEC and 
ENOC. 
Table S11: ENOC models using 5-year censoring on survival data, for comparison 
with previously published 5-year censored data from EC. See also Figure 3. 
Abbreviations used in this manuscript 
COEUR - Canadian Ovarian Experimental Unified Resource 
COSMIC - Catalogue of Somatic Mutations in Cancer 
dbSNP - Database of Single Nucleotide Polymorphisms 
DSS - Disease-specific survival 
EC - Endometrial carcinoma 
EEC - Endometrioid endometrial carcinoma 
ENOC - Endometrioid ovarian carcinoma 
FFPE - Formalin-Fixed, Paraffin-Embedded 
FIGO - Fédération Internationale de Gynécologie et d'Obstétrique 
GER - Germany 
G - Grade 
HGSOC - High-grade serous ovarian carcinoma 
HR - Hazard Ratio 
IHC - Immunohistochemistry 
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MMRd - Mismatch repair deficient (subtype designation) 
NGS - Next Generation Sequencing 
NL - Netherlands 
NSMP - No specific molecular profile (subtype designation) 
NOS - Not otherwise specified 
OS - Overall survival 
OVCARE - British Columbia's Gynecological Cancer Research team 
p53abn - p53 abnormal (subtype designation showing abnormal p53 IHC staining 
pattern) 
PFS - Progression-free survival 
POLE - DNA Polymerase Epsilon 
POLEmut - pathogenic POLE mutant (subtype designation) 
ProMisE - Proactive Molecular Risk Classifier for Endometrial Cancer 
TCGA - The Cancer Genome Atlas network  
TMA - Tissue Microarray 
TP53 - Tumor suppressor Protein 53 
UK - United Kingdom 
VAF - Variant Allele Frequency 
VUS - (Somatic) Variants of Unknown Significance 
WGS - Whole genome sequencing 
ACKNOWLEDGEMENTS 
We thank all the study participants who contributed to this study and all the 
researchers, clinicians, technical and administrative staff who have made this work 
possible. Further we thank Dr. Lien Hoang and Dr. Blake Gilks for technical input 
and advice. This study uses resources provided by the Canadian Ovarian Cancer 
Research Consortium’s COEUR biobank funded by the Terry Fox Research Institute 
and managed and supervised by the Centre hospitalier de l’Université de Montréal 
(CRCHUM). The Consortium acknowledges contributions to its COEUR biobank 
from Institutions across Canada (for a full list see 
http://www.tfri.ca/en/research/translational-research/coeur/coeur_biobanks.aspx). 
This project also received technical and data management support from Calgary 
Laboratory Services and OVCARE, through the Cheryl Brown Ovarian Cancer 
Outcomes Unit and the Genetic Pathology Evaluation Centre. The authors thank all 
sources of support for this project. Major funding was provided by the Terry Fox 
Research Institute’s pan-Canadian Ovarian Cancer study (COEUR: Canadian 
Ovarian Experimental Unified Resource). UK study samples were collected as part 
of the SIGNPOsT study, which received funding from Barts Charity (R. Manchanda 
and N. Singh). A. Talhouk is funded through a Michael Smith Foundation for Health 
Research Scholar Award. J.N. McAlpine is funded through the BC Cancer 
Foundation Clinician Scientist Award. M. de Bruyn is funded through a Dutch Cancer 
Society Young Investigator Grant. R. Manchanda is funded by the Barts Charity 
(SIGNPOST study). T. Bosse is funded through a Dutch Cancer Society Young 
Investigator Grant (10418). M. Köbel received support through the Calgary 
Laboratory Services research support fund (RS19-609). M.S. Anglesio is funded 
through a Michael Smith Foundation for Health Research Scholar Award and the 
 
19 
Janet D. Cottrelle Foundation Scholars program managed by the BC Cancer 
Foundation. BC's Gynecological Cancer Research team (OVCARE) receives support 
through the BC Cancer Foundation and The VGH+UBC Hospital Foundation 





1. Kobel, M., et al., Ovarian carcinoma subtypes are different diseases: implications for 
biomarker studies. PLoS Med, 2008. 5(12): p. e232. 
2. Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian 
carcinoma. Nature, 2011. 474(7353): p. 609-15. 
3. Kobel, M., et al., Differences in tumor type in low-stage versus high-stage ovarian 
carcinomas. Int J Gynecol Pathol, 2010. 29(3): p. 203-11. 
4. Committee on the State of the Science in Ovarian Cancer Research, et al., eds. 
Ovarian Cancers: Evolving Paradigms in Research and Care. 1 ed. Institute of 
Medicine, ed. E. National Academies of Sciences, and Medicine. 2016, The National 
Academies Press: Washington, D.C. 
5. Anglesio, M.S. and P.J. Yong, Endometriosis-associated Ovarian Cancers. Clin 
Obstet Gynecol, 2017. 60(4): p. 711-727. 
6. Matias-Guiu, X. and C.J.R. Stewart, Endometriosis-associated ovarian neoplasia. 
Pathology, 2018. 50(2): p. 190-204. 
7. Anglesio, M.S., et al., Synchronous Endometrial and Ovarian Carcinomas: Evidence 
of Clonality. J Natl Cancer Inst, 2016. 108(6): p. djv428. 
8. Schultheis, A.M., et al., Massively Parallel Sequencing-Based Clonality Analysis of 
Synchronous Endometrioid Endometrial and Ovarian Carcinomas. J Natl Cancer Inst, 
2016. 108(6): p. djv427. 
9. Kurman, R.J., et al., eds. WHO Classification of Tumours of Female Reproductive 
Organs. 4 ed. WHO Classification of Tumours. Vol. 6. 2014, IARC-WHO Press: Lyon, 
France. 316. 
10. McConechy, M.K., et al., Ovarian and endometrial endometrioid carcinomas have 
distinct CTNNB1 and PTEN mutation profiles. Mod Pathol, 2014. 27(1): p. 128-34. 
11. McConechy, M.K., et al., Endometrial Carcinomas with POLE Exonuclease Domain 
Mutations Have a Favorable Prognosis. Clin Cancer Res, 2016. 22(12): p. 2865-73. 
12. Hoang, L.N., et al., Polymerase Epsilon Exonuclease Domain Mutations in Ovarian 
Endometrioid Carcinoma. Int J Gynecol Cancer, 2015. 25(7): p. 1187-93. 
13. Peres, L.C., et al., Invasive Epithelial Ovarian Cancer Survival by Histotype and 
Disease Stage. J Natl Cancer Inst, 2019. 111(1): p. 60-68. 
14. Rambau, P.F., et al., Association of p16 expression with prognosis varies across 
ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J 
Pathol Clin Res, 2018. 4(4): p. 250-261. 
15. Le Page, C., et al., Characteristics and outcome of the COEUR Canadian validation 
cohort for ovarian cancer biomarkers. BMC Cancer, 2018. 18(1): p. 347. 
16. Armstrong, D.K., et al. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines®) Ovarian Cancer Including Fallopian Tube Cancerand Primary 
Peritoneal Cancer. 2019. Version 3.2019. 
17. Colombo, N., et al., ESMO–ESGO consensus conference recommendations on 
ovarian cancer: pathology and molecular biology, early and advanced stages, 
borderline tumours and recurrent disease†. Annals of Oncology, 2019. 30(5): p. 672-
705. 
18. Cancer Genome Atlas Research Network, K.C., Schultz N, Cherniack AD, Akbani R, 
Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding 
 
20 
L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA, Integrated genomic 
characterization of endometrial carcinoma. Nature, 2013. 497(7447): p. 67-73. 
19. Talhouk, A., et al., A clinically applicable molecular-based classification for 
endometrial cancers. Br J Cancer, 2015. 113(2): p. 299-310. 
20. Stelloo, E., et al., Improved Risk Assessment by Integrating Molecular and 
Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of 
the PORTEC Cohorts. Clin Cancer Res, 2016. 22(16): p. 4215-24. 
21. McAlpine, J., A. Leon-Castillo, and T. Bosse, The rise of a novel classification system 
for endometrial carcinoma; integration of molecular subclasses. J Pathol, 2018. 
244(5): p. 538-549. 
22. Parra-Herran, C., et al., Molecular-based classification algorithm for endometrial 
carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant 
groups. Mod Pathol, 2017. 30(12): p. 1748-1759. 
23. Cybulska, P., et al., Molecular profiling and molecular classification of endometrioid 
ovarian carcinomas. Gynecol Oncol, 2019. 154(3): p. 516-523. 
24. Kobel, M., et al., An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. 
Int J Gynecol Pathol, 2016. 35(5): p. 430-41. 
25. Dieters-Castator, D.Z., et al., Proteomics-Derived Biomarker Panel Improves 
Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian 
Carcinoma. Clin Cancer Res, 2019. 25(14): p. 4309-4319. 
26. McConechy, M.K., et al., Detection of DNA mismatch repair (MMR) deficiencies by 
immunohistochemistry can effectively diagnose the microsatellite instability (MSI) 
phenotype in endometrial carcinomas. Gynecol Oncol, 2015. 137(2): p. 306-10. 
27. Roth, R.M., et al., Discordant Mismatch Repair Protein Immunoreactivity in Lynch 
Syndrome-Associated Neoplasms: A Recommendation for Screening 
Synchronous/Metachronous Neoplasms. Am J Clin Pathol, 2016. 146(1): p. 50-6. 
28. Kobel, M., et al., Optimized p53 immunohistochemistry is an accurate predictor of 
TP53 mutation in ovarian carcinoma. J Pathol Clin Res, 2016. 2(4): p. 247-258. 
29. Kobel, M., et al., Interpretation of P53 Immunohistochemistry in Endometrial 
Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol, 2019. 38 Suppl 
1: p. S123-S131. 
30. Kommoss, S., et al., Final validation of the ProMisE molecular classifier for 
endometrial carcinoma in a large population-based case series. Ann Oncol, 2018. 
29(5): p. 1180-1188. 
31. Leon-Castillo, A., et al., Interpretation of somatic POLE mutations in endometrial 
carcinoma. J Pathol, 2020. 250(3): p. 323-335. 
32. Singh, N., et al., Extrauterine high-grade serous carcinomas with bilateral adnexal 
involvement as the only two disease sites are clonal based on tp53 sequencing 
results: implications for biology, classification, and staging. Mod Pathol, 2017. 
33. Do, H. and A. Dobrovic, Sequence artifacts in DNA from formalin-fixed tissues: 
causes and strategies for minimization. Clin Chem, 2015. 61(1): p. 64-71. 
34. Leon-Castillo, A., et al., Clinicopathological and molecular characterisation of 
'multiple-classifier' endometrial carcinomas. J Pathol, 2020. 250(3): p. 312-322. 
35. Balduzzi, S., G. Rucker, and G. Schwarzer, How to perform a meta-analysis with R: a 
practical tutorial. Evid Based Ment Health, 2019. 22(4): p. 153-160. 
36. Talhouk, A., et al., Confirmation of ProMisE: A simple, genomics-based clinical 
classifier for endometrial cancer. Cancer, 2017. 123(5): p. 802-813. 
37. Wang, Y.K., et al., Genomic consequences of aberrant DNA repair mechanisms 
stratify ovarian cancer histotypes. Nat Genet, 2017. 49(6): p. 856-865. 
38. Setiawan, V.W., et al., Type I and II endometrial cancers: have they different risk 
factors? J Clin Oncol, 2013. 31(20): p. 2607-18. 
39. Wentzensen, N., et al., Ovarian Cancer Risk Factors by Histologic Subtype: An 




40. Clarke, M.A., et al., A prospective clinical cohort study of women at increased risk for 
endometrial cancer. Gynecol Oncol, 2020. 156(1): p. 169-177. 
41. Soong, T.R., et al., The fallopian tube, "precursor escape" and narrowing the 
knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol, 2019. 
152(2): p. 426-433. 
42. Temko, D., et al., Somatic POLE exonuclease domain mutations are early events in 
sporadic endometrial and colorectal carcinogenesis, determining driver mutational 
landscape, clonal neoantigen burden and immune response. J Pathol, 2018. 245(3): 
p. 283-296. 
43. McAlpine J.N., N.R., Kommoss S., Church D., Bellone S., Clarke B., DeLair D., 
Leung S., Britton H., Bernardini M., Lee C.H., Ngeow J.Y., Soslow R., Brucker S., 
Koebel M., Santin A., Gilks C.B., Goodfellow P., Bosse T., Talhouk A., Survival 
benefit in women with endometrial cancers harboring pole mutations may be 
independent of adjuvant therapy, in 17th Biennial Meeting of the International 
Gynecologic Cancer Society. 2018, Int J Gynecol Cancer: Kyoto, Japan. p. 42. 
44. Nakonechny, Q.B. and C.B. Gilks, Ovarian Cancer in Hereditary Cancer 
Susceptibility Syndromes. Surg Pathol Clin, 2016. 9(2): p. 189-99. 
45. Rambau, P.F., et al., Significant frequency of MSH2/MSH6 abnormality in ovarian 
endometrioid carcinoma supports histotype-specific Lynch syndrome screening in 
ovarian carcinomas. Histopathology, 2016. 69(2): p. 288-97. 
46. Merck Sharp & Dohme Corp. (KEYTRUDA Prescribing information). U.S. Food & 
Drug Administration website. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s040lbl.pdf, 
Revised 2019. Access date 03/27/2020. 
47. Regulatory Decision Summary for Keytruda. Health Canada. https://hpr-
rps.hres.ca/reg-content/regulatory-decision-summary-
detail.php?lang=en&linkID=RDS00514, 2019. Access date 04/04/2020. 
48. Rambau, P., et al., Association of Hormone Receptor Expression with Survival in 
Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. Int J 
Mol Sci, 2017. 18(3). 
49. Wang, L., et al., Nuclear beta-catenin and CDX2 expression in ovarian endometrioid 
carcinoma identify patients with favourable outcome. Histopathology, 2019. 74(3): p. 
452-462. 
50. Hollis, R.L., et al., Hormone receptor expression patterns define clinically meaningful 
subgroups of endometrioid ovarian carcinoma. Gynecol Oncol, 2019. 155(2): p. 318-
323. 
51. Torre, L.A., et al., Ovarian cancer statistics, 2018. CA Cancer J Clin, 2018. 68(4): p. 
284-296. 
52. Parra-Herran, C., et al., FIGO Versus Silverberg Grading Systems in Ovarian 
Endometrioid Carcinoma: A Comparative Prognostic Analysis. Am J Surg Pathol, 
2019. 43(2): p. 161-167. 
53. Singh, N., et al., p53 immunohistochemistry is an accurate surrogate for TP53 
mutational analysis in endometrial carcinoma biopsies. J Pathol, 2020. 250(3): p. 
336-345. 
54. Talhouk, A., et al., Molecular classification of endometrial carcinoma on diagnostic 
specimens is highly concordant with final hysterectomy: Earlier prognostic 
information to guide treatment. Gynecol Oncol, 2016. 143(1): p. 46-53. 
55. Gilks, C.B., et al., Tumor cell type can be reproducibly diagnosed and is of 
independent prognostic significance in patients with maximally debulked ovarian 
carcinoma. Hum Pathol, 2008. 39(8): p. 1239-51. 
56. Werner, H.M., et al., A discordant histological risk classification in preoperative and 
operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. 
Eur J Cancer, 2013. 49(3): p. 625-32. 
 
